Page 46 - MemoriaCIBER-2017ENG

Arterial pathology, myocardial ischaemia and structural pathology of the heart
Coordinators: David García-Dorado / Alberto San Román
Programme 2 of the CIBERCV on arterial disease, myocardial ischaemia- reperfusion and structural heart disease has published some cooperative articles with great impact in 2017 These include a major study which proved the capacity of di erent image markers in early cardiac magnetic resonance (Published in the Journal of the American College of Cardiology – Cardiovascular Imaging) The prognostic implications of haemo-erythrocyte proteins in these patients have also been described (published in Thrombosis Haemostasis) The SIOVAC randomised test analysed the e ect of sildena l on persistent pulmonary hypertension after valve surgery The ndings of this study, published in the European Heart Journal, are sure to change the recommendations of international guides on this subject
Programme 2 also published cooperative articles which have produced substantial progress in the understanding of the mechanisms of this group of diseases, such as the in-depth characterisation of the proteomic footprint of myocardial ischaemic reperfusion published in Scienti c Reports, the identi cation of the role of miRNA in the prevention of damage through reperfusion with urocortin, published in Scienti c Reports, or the discovery of the role of nitric oxide in aneurysmatic aortic disease, in particular, its possible participation in the cell signalling responsible for the phenotype of Marfan syndrome, published in Nature Medicine This study will be translated for patients in clinical tests which are being planned to start in 2018
The transfer of knowledge generated in Programme 2 has progressed through patents and other initiatives Patents have been submitted on biomechanical sensors applicable to the di erential diagnosis between myocardial ischaemia and myocarditis (European Patent), an oral treatment to prevent adverse post- ischaemic remodelling by inhibiting the activation of calpain (European patent) or new risk biomarkers for cardiovascular diseases (International patent, already with a licence) The creation of a multicentre platform for preclinical research into lesions by reperfusion (CIBERCLAP) is one of the most important of other prominent aspects of transfer, as well as the introduction of genetically modi ed mouse models which are o ered to all the participants of CIBERCV
The power of cooperative research in Programme 2 is clearly proven by initiatives such as those of the acute coronary syndrome, low ow aortic stenosis, aortic regurgitation or transcatheter aortic valve implantation, some of which generate competitive funds, such as the registration of congenital heart disease or the registration of sudden death in congenital heart disease, both nanced by the Instituto Nacional de Salud (Instituto de Salud Carlos III) In 2017, many patients were included in randomised clinical tests in patients with acute myocardial infarction and bicuspid aortic valve
Some of the competitive subsidies obtained in Programme 2 were the European initiative H2020 COST on cardioprotection against reperfusion injury, EU-Cardioprotect, with the participation of several groups from this programme, as an example of the international outreach of the CIBERCV
46 CIBER ANNUAL REPORT 2017